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Abstract
Background: An early sepsis-induced acute kidney injury (sepsis-AKI) biomarker is currently in needed. Urinary
neutrophil gelatinase-associated lipocalin (uNGAL) is a candidate of sepsis-AKI biomarker but with different cut-
point values. Urinary exosomal activating transcriptional factor 3 (uATF3) has been mentioned as an interesting
biomarker.
Methods: We conducted experiments in mice and a prospective, multicenter study in patients as a proof of concept
that urine exosome is an interesting biomarker. An early expression of ATF3 in kidney of CD-1 mice at 6 h after cecal
ligation and puncture implied the possibility of uATF3 as an early sepsis-AKI biomarker. Increase serum creatinine
(Scr) ≥0.3 mg/dL from the baseline was used as an AKI diagnosis and urine was analyzed for uATF3 and uNGAL.
Patients with baseline Scr at admission ≥1.5 mg/dL were excluded.
Results: The analysis showed higher Scr, uNGAL and uATF3 in patients with sepsis-AKI in comparison with patients
with sepsis-non-AKI and healthy volunteers. A fair correlation, r2 = 0.47, between uATF3 and uNGAL was showed in
sepsis-AKI group with Scr ≥2 mg/dL. To see if uATF3 could be an early sepsis-AKI biomarker, urine sample was
collected daily during the first week of the admission. In sepsis-AKI and sepsis-non-AKI groups, uNGAL were 367
± 43 ng/mL and 183 ± 23 ng/mL, respectively; and uATF3 were 19 ± 4 ng/mL and 1.4 ± 0.8 ng/mL, respectively.
With the mean value of uNGAL and uATF3 in sepsis AKI as a cut-off level, AUROC of uNGAL and uATF3 were
64% (95% CI 0.54 to 0.74) and 84% (95% CI 0.77 to 0.91), respectively.
Conclusions: Urine exosome is an interesting source of urine biomarker and uATF3 is an interesting sepsis-AKI
biomarker.
Keywords: Activating transcriptional factor 3, Acute kidney injury, Biomarker, Neutrophil gelatinase-associated
lipocalin, Urine exosome
Background
Sepsis is the systemic inflammatory response syndrome
(SIRS) in the response of infectious processes regardless
of organisms [1]. Sepsis is a world-wide health care
problem and a leading cause of death of patients in
intensive care unit [2]. On the other hand, acute kidney
injury (AKI) is a clinical syndrome of an abrupt renal
dysfunction leading to uremic toxins accumulation and
several organs dysfunction [3]. It is interesting that more
than 50% of patients with sepsis develop AKI and sepsis
patients with AKI had a higher mortality rate [4, 5]. The
definition of sepsis-induced AKI (sepsis-AKI) is an AKI
occurs simultaneously or subsequently after sepsis with
the exclusion of other causes of AKI [2]. Despite an
advance in an understanding of pathogenesis and sepsis-
AKI therapy in animal models, the translational research
into a human condition is currently unsuccessful. This,
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at least in part, demonstrates the requirement for early
sepsis-AKI biomarkers [6]. Serum creatinine (Scr), a
current standard biomarker of AKI, is a late renal injury
biomarker which does not a good representative of
sepsis-AKI [7–10]. Thus, several potential biomarkers
for detecting sepsis-AKI have been studies. Urinary
neutrophil gelatinase associated lipocalin (uNGAL) is
one of the promising sepsis-AKI biomarker, but still
have a debate on the cut-off value [11, 12]. The difference
cut-off value of uNGAL might due to the possibility of dif-
ferent sources of neutrophil gelatinase-associated lipocalin
(NGAL), such as neutrophil and other internal organs,
etc., especially, in patients with sepsis [13, 14].
Exosomes are the nano-vesicles released by most of the
cells as a method of cell communication for either normal
physiologies or many pathological processes [15]. These
nano-vesicles are some parts of cell membrane containing
several proteins including the genetic materials [16, 17]. In
another word, exosome is a membrane-protected source
of biological materials. Hence, urine exosome is an inter-
esting source of urine biomarkers [17–19]. Activating
transcription factor 3 (ATF3) is one of the transcriptional
factor protected inside urine exosome which expressed in
urine of AKI in patients and animal models [20, 21]. Renal
ATF3 is activated in mouse models of ischemic reperfu-
sion injury and cisplatin induced nephrotoxicity [22, 23].
Interestingly, ATF3 downstream functions are anti-
apoptosis and anti-inflammation through the attenuation
of pro-inflammatory mediators and the alteration of the
chromatin binding site in transcriptional factors [21, 22,
24, 25]. Hence, ATF3 should be involved in the patho-
physiology of sepsis, AKI and sepsis-AKI. Unfortunately,
ATF3 detection in total urine and non-exosomal urine
fraction is inconsistent [20, 21] due, in part, to the deg-
radation of transcriptional factor in urine [26]. But
ATF3 seems to be protected inside exosome membrane
and allow easier detection [20]. Therefore, we hypothe-
sized that urinary exosomal ATF3 (uATF3) should be an
interesting biomarker of sepsis-AKI.
Materials and methods
Cecal ligation and puncture sepsis model and kidney
immunohistochemistry
The US National Institutes of Health (NIH) criteria and
protocols were followed. Male, 8–10 week old CD-1
mice (National Laboratory Animal Center, Nakhon
Pathom, Thailand) were used. Cecal ligation and punc-
ture sepsis model (CLP) was performed under isoflurane
anesthesia as previously details [10, 27]. In brief, cecum
was ligated at 12 mm from the cecal tip, punctured with
a 21-gauge needle and squeezed for a small amount of
feces. Supplementary fluid, 1 mL of normal saline, was
administered at the post-operational period. However,
antibiotic was not used because the effect of antibiotic
to urinary exosome was uncertain. Only the abdominal
incision for cecal identification was done in sham group.
Blood (50 μL) was collected through tail vein nicking for
the time-point analysis of mouse serum NGAL (sNGAL)
(R&D systems, MN, USA) and serum creatinine (Scr)
(QuantiChrom Creatinine assay DICT-500, Hayward,
CA, USA). Mice were euthanized under isoflurane
anesthesia. Kidney, liver and spleen were put in liquid
nitrogen then kept at −80 °C until used. Kidney was also
fixed in 10% neutral buffered formalin and embedded in
paraffin for the immunohistochemical section of 45 μm
thickness with anti-mouse NGAL (R&D systems, MN,
USA) and anti-mouse ATF3 (Santa cruz, CA, USA) as
previously described [27]. Western Blot analysis of tissue
ATF3 and activated caspase-3 (Cell Signaling, MA, USA)
were also performed. The protocol for the experiment
was approved by the Animal Experimentation Ethics
Committee of Chulalongkorn University.
Patient selections
Spot urine collection was performed during January
2014 to August 2014 at the King Chulalongkorn Memorial
Hospital (KCMH) and three other general hospitals. To
include patients with documented early sepsis-AKI during
the hospitalization, all adult patients (age more than
18-year-old) in internal medicine ward with sepsis by
the demonstration of systemic inflammatory response
syndrome (SIRS) with the evidence or the suspicious of
infectious causes [1]. Additionally, AKI defined as Scr
increase ≥0.3 mg/dL from baseline followed KDIGO
and AKIN criteria [3]. Then sepsis-induced AKI (sepsis-
AKI) defined as sepsis with Scr increase ≥0.3 mg/dL from
baseline [3]. Otherwise, patients with sepsis but Scr
increase ≤0.3 mg/dL were classified as sepsis-non-AKI.
Exclusion criteria were (i) patients with the baseline Scr
(first Scr measured) higher than 1.5 mg/dL or other his-
tory of chronic kidney diseases, (ii) pregnant women, (iii)
chronic systemic diseases with proteinuria such as
diabetic nephropathy, lupus nephritis, etc.; (iv) ob-
structive uropathy, and (v) post kidney transplant-
ation. Baseline Scr were retrospectively reviewed
from the medical records of at least 3-month earlier
from the participant hospitals. Patients with sepsis
with elevated Scr at the time of admission was firstly
determined as sepsis induced acute kidney injury
unless they met the exclusion criteria (1st time Scr
>1.5 mg/dL). Renal sonogram was used to exclude the
preexisting chronic kidney disease (CKD) in some
patients. Then the participants were followed with daily
first morning spot urine and serum samples collection
during the 1st week of admission period.
Of all 382 patients, most of the patients had underlying
diseases and only 139 patients were included and approxi-
mately half of these patients were sepsis-AKI (n = 79) (Fig. 1
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and Table 1) implied the importance of AKI in sepsis. Then
8 patients with sepsis-AKI were randomly selected by pro-
pensity score matched in gender, age and comorbidity to
compare with 8 healthy volunteers group served as discov-
ery set. Subsequently, all urine samples from patients who
underwent the new onset of sepsis-AKI (n = 79) during the
1st week of admission were analyzed in comparison with
sepsis-non-AKI (n = 60). Of note, there were 17 and 11 pa-
tients of sepsis-AKI and non sepsis-AKI, respectively,
transferred to intensive care unit. For the urine collection,
urine was centrifuged at 1,000x g for 10 min to remove
debris, and stored at −80 °C until used.
This study was approved by the Institutional Review
Board of Faculty of Medicine, Chulalongkorn University,
Bangkok, Thailand and adhered to ARRIVE guideline/
methodology.
Measurement of serum creatinine, urine NGAL and
urinary exosomal ATF3 of patients’ sample
uNGAL and Scr were measured by ELISA assay (R&D
systems, MN, USA) and enzymatic based automated
analyzer, respectively. Urinary exosomal ATF3 was
measured by Western blot analysis with the quantita-
tive analysis by the calculation from recombinant ATF3
(Santa cruz, CA, USA). Urine exosomes were isolated
by the differential centrifugation method as described
previously [20]. In brief, frozen urine was thawed and
10 mL of urine was centrifuged at 17,000x g for 15 min.
Then the supernatant from the first spin was centri-
fuged at 200,000x g for 1 h and suspended by 50 μL of
1% SDS in 50 mM Tris. The analysis of Tumor suscep-
tible gene 101 (TSG101), one of the exosome bio-
markers [28], was used to support the efficiency of this
method. The initial urinary exosome-associated pro-
teins (50 μL) were loaded in different volume into each
well depended on urine creatinine (Ucr). This method
of exosome biomarker normalization by Ucr was also
described previously [20, 29]. The quantitative values of
ATF3 by Western blot analysis were calculated from
the density of 3 known concentrations of recombinant
ATF3 (MyBiosource, CA, USA) loaded in every gel
along with the samples.
Western blot analysis
Sample protein were separated by 1day sodium dodecyl
sulfate (SDS)–polyacrylamide gel electrophoresis and
transferred into a nitrocellulose membrane under Tow-
bin transfer buffer (TBS). The membranes were blocked
with 5% milk in TBS plus 0.1% tween-20 for 1 h at room
temperature then probed overnight at 4 °C with anti-
mouse ATF3 and anti-mouse activated caspase-3 (Cell
Signaling, MA, USA) for mouse internal organs or with
anti-human ATF3 (Santa cruz, CA, USA) and anti-
TSG101 (Cell Signaling, MA, USA) for urine exosome
samples. To see if there is TSG101 in the non-exosome
urine fraction after centrifuged at 200,000x g (soup),
acetone precipitation was used to concentrate the soluble
protein in soup fraction before Western blot analysis in
parallel with urine exosome fraction (Fig. 4a). For the
visualization, the blot was incubated with appropriate
horseradish peroxidase-linked secondary antibodies
(1:5,000) (Jackson ImmunoResearch Laboratories, PA,
USA) and visualized for the chemiluminescence with
SuperSignal® (Thermo Scientific, IL, USA) and C-DiGit®
Blot Scanner (Li-Cor BioTech, NE, USA).
Statistical analysis
Data was demonstrated as mean ± SD and the differences
between groups were examined for statistical significance
by unpaired student t-test or one-way analysis of variance
(ANOVA) with Tukey’s comparison test in the analysis of
experiments with 2 and 3 groups, respectively. Time-point
data was examined by two-way ANOVA with Bonferroni
post hoc analysis. Survival analysis was performed by log-
rank test. P value <0.05 was considered to be a statistically
significant. Area under receiver operating characteristic
(AUROC), sensitivity and specificity were calculated in
relative to increased Scr ≥0.3 mg/dL from baseline as the
Fig. 1 Consort-type flowchart showing patient selection
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sepsis-AKI diagnosis. The logistic regression model was
fitted to the data to determine the influence of uNGAL
and uATF3 and also adjusted by those clinical variables
(age, comorbidity, APACHE II score) that were shown to
have influence on the risk of AKI. The ability of these
models to predict AKI was analyzed by the Hosmer–
Lemeshow goodness-of-fit test. Then, the discriminative
ability of uNGAL and uATF3 for AKI diagnosis was deter-
mined by the AUROC. In addition, the net reclassification
improvement (NRI) and the category-free NRI (cfNRI)
were performed to demonstrate the additive value of pre-
existing risk prediction model. NRI demonstrates the
quality of predicted probabilities as a consequence of
adding a new marker to the existing model. Statistical ana-
lysis was performed using SPSS for Windows 15.0 (SPSS
for Windows; Chicago, IL) and GraphPad Prism (version
6.00; GraphPad Software, La Jolla, CA) software. Reclassi-
fication analyses were performed in R using the regression
modelling strategies (rms) package for calculating NRI
and cfNRI.
Results
Both NGAL and ATF3 expressed early in kidney of sepsis
mice
Lethal sepsis model of cecal ligation and puncture (CLP)
with survival rate at 25% (Fig. 2a) was used. Although
Table 1 Patient characteristics
Characteristics Healthy volunteers (n = 8) Sepsis-AKI (n = 79) Sepsis-non-AKI (n = 60) p-value
Mean age, yr (SD) 43.1 (10.2) 63.3 (13.3) 51.5 (18.5) <0.0001
Men (%) 3 (37.5) 52 (65.8) 28 (46.7) 0.04
Baseline Scr (mg/dL) 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.3 0.10
All-time point Scr (mg/dL)
Median (P25-P75) 0.9 (0.8-1.0) 3.2 (1.7-4.3) 1.0 (0.8-1.3) <0.0001
All-time point MDRD Scr-eGFR
(mL/min/1.73 m2) 109.3 33.5 64.8 <0.0001
Median (P25-P75) (92.1-128.3) (19.8-42.2) (48.2-70.2)
APACHE II score (SD) - 22 (1.9) 18 (6.4) <0.0001
Principle comorbidities (%)
Hypertension - 26 (32.9) 22 (36.7) 0.77
Cardiovascular disease - 10 (12.7) 6 (10.0) 0.82
COPD - 7 (8.9) 1 (1.7) 0.15
No known underlying disease - 26 (32.9) 18 (30.0) 0.86
Causes of sepsis
Pneumonia - 36 (45.6) 22 (36.7) 0.38
Urinary tract infection - 28 (35.4) 17 (28.3) 0.48
Intra-abdominal infection - 7 (8.9) 12 (20.0) 0.10
Soft tissue infection - 0 (0) 7 (11.7) 0.006
Tropical infection - 8 (10.1) 2 (3.3) 0.23
Outcomes
Severe sepsis (%) - 43 (54.4) 18 (30.0) 0.007
Intensive care unit admission (%) - 31 (39.2) 13 (21.7) 0.04
In-hospital length of stay, days (SD) - 63 (15.6) 30 (11.9) <0.0001
Dialysis (%) - 25 (31.6) 0 (0) <0.0001
Mortality (%) - 9 (11.4) 4 (6.7) 0.52
AKI severity (%)
AKIN 1 - 38 (48.1) 0 <0.0001
AKIN 2 - 30 (38.0) 0 <0.0001
AKIN 3 - 28 (35.4) 0 <0.0001
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary
disease; MDRD Scr-eGFR, GFR estimated from Scr using the Modification of Diet in Renal Disease equation; P25-P75, 25th percentile to 75th percentile; Scr,
serum creatinine
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Scr did not significantly increase in the first 6 h after
CLP, mice clinical symptoms of illness and serum NGAL
(sNGAL) were observed at 6 h of the surgery (Fig. 2b)
consistent with previous publications [10, 27]. At 18 h
both Scr and sNGAL were higher than the baseline
(Fig. 2b). Because at 6 h-post CLP was the earliest time-
point of increased sNGAL, kidney histology at 6 h after
CLP was analyzed for NGAL and ATF3 as early-sepsis
biomarker candidates. Indeed, NGAL expressed in cyto-
plasm and ATF3 expressed in nuclei of the renal tubular
cell (Fig. 2c, d) at 6 h after CLP but not in sham group
(data not showed). Moreover, the activated caspase-3
also detectable in kidney at 6 h of CLP by Western blot
analysis (Fig. 2e, f ). In addition, ATF3 and NGAL
expressed in kidney, liver and spleen at 6 h of CLP sepsis
mice (Fig. 3) but not in sham (showed only kidney). Due
to an early anuria in sepsis mice, we could not analyze
urine biomarker in this model.
High urinary NGAL (uNGAL) and urinary exosomal
ATF3 (uATF3) in an initial analysis of patients with
sepsis-induced acute kidney injury (Sepsis-AKI)
The presentation of exosome in urine with extraction pro-
cedures was demonstrated by TSG101 (Fig. 4a). By using
propensity score matched in gender, age and comorbidity, 8
from 79 patients with sepsis-AKI were randomly selected
for the analysis. Scr of patients with sepsis-AKI and healthy
volunteers were 2.15 ± 0.22 and 0.97 ± 0.02 mg/dL,
Fig. 2 Survival analysis of the cecal ligation and puncture (CLP) model used in the study (a) and time-course of serum neutrophil gelatinase associated
lipocalin (sNGAL) and serum creatinine (Scr) (b) were demonstrated. The representative pictures of the immunohistochemistry of mouse
kidney after 6 h of CLP sepsis surgery for NGAL (c) and activating transcriptional factor 3 (ATF3) (d). NGAL and ATF3 were demonstrated
in cytoplasm/brush border and nuclei of cortical renal tubules cells, respectively, and both parameters could not be detected in kidney
of sham surgery (data not showed). Additionally, activated caspase-3 was also analyzed in kidney sample at 6 h of CLP and sham surgery
(e). The comparison of Caspase-3 Western Blot density between kidney of sham and CLP group measured from C-DiGit® Blot Scanner
was also showed (f)
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Fig. 3 The Western blot analysis of ATF3 in different organs of mice at 6 h after cecal ligation and puncture sepsis surgery (upper panel) and the
density scoring (lower panel) (n = 3-5/group). The reciprocal organs of mice at 6 h after sham surgery were undetectable (data showed only
kidney of sham group)
Fig. 4 TSG101 (MW 49 kDa) was demonstrated in esosome fraction of urine (Exosome) supported the efficiency of urine exosome extraction
procedure and TSG101 could not be detected in non-exosome urine fraction (soup) (a). The cross-sectional analysis from sepsis-AKI patients
regardless of the onset of sepsis-AKI for serum creatinine (Scr) (b), urinary neutrophil gelatinase associated lipocalin (uNGAL) (c) and urinary
activating transcriptional factor 3 (uATF3) (d) were showed (n = 8/group)
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respectively (p <0.001) (Fig. 4b). With simultaneous
analysis, uNGAL and uAFT3 of sepsis-AKI versus
healthy volunteers were 1,909 ± 838 versus 17 ± 4 ng/
mL and 16 ± 4 and 0 ng/mL, respectively (Fig. 4c, d).
Interestingly, uATF3 was non-detectable in all healthy
volunteers and both uATF3 and uNGAL associated
with AKI severity by AKIN classification. The median
value of uATF3 versus uNGAL for AKIN stage 1, 2
and 3 were 8.5-11.7, 14.2-16.7, and 18.2-22.3 ng/mL
versus 121–374, 529–871, and 1,071-1,533 ng/mL,
respectively (p <0.001 among each stage). However, the
correlation between all uNGAL and uATF3 was limited
(r2 = 0.39) but increased (r2 = 0.47) with the selection of
Scr ≥2 mg/dL. With Scr < 2 mg/dL, there was even
lesser correlation (r2 = 0.26).
Urinary NGAL (uNGAL) and urinary exosomal ATF3
(uATF3) in a 7 days follow-up of patients with sepsis-in-
duced acute kidney injury (Sepsis-AKI) showed a potential
as an early sepsis-AKI biomarkers
There were data from 79 and 60 patients with
sepsis-AKI and non sepsis-AKI, respectively, avail-
able for the analysis. Of note, 10 from 79 patients
(12.7%) in sepsis-AKI group were classified as septic
shock. Other patients were categorized as severe
sepsis due to there was some organ injuries in these
patients. Because there was different onset of sepsis-
AKI during 1 week of the follow-up, all data of the
7 days follow-up were combined. With the combin-
ation data, Scr, uNGAL and uATF3 of sepsis-AKI
and sepsis-non-AKI group were 1.25 ± 0.11 mg/dl,
367 ± 43 ng/mL and 19 ± 4 ng/mL and 0.97 ±
0.02 mg/dL, 183 ± 23 ng/mL and 1.4 ± 0.8 ng/mL, re-
spectively (p <0.001 all) (Fig. 5a-c). Of note, most of
the patients in this study were non-oligulic sepsis-
AKI (68/79 or 86%) (urine output more than
0.5 mL/kg/h) during the observational period. As
expected, uNGAL in sepsis-AKI was higher than
sepsis non-AKI group reciprocal to previous studies
[30]. Interestingly, uATF3 was also higher in sepsis-
AKI group. It is interesting that uATF3 was
undetectable in nearly all time-points of sepsis non-
AKI group implied the high specificity of uATF3 for
sepsis-AKI (Fig. 5c). Although both uNGAL and
uATF3 correlated with Scr levels, uATF3 provided
the better differentiation between sepsis-AKI and
sepsis non-AKI (Fig. 5d, e).
To explore an early sepsis-AKI biomarker poten-
tial, uNGAL and uATF3 at 1 day before and at 1st
and 2nd day of Scr ≥0.3 mg/dL from baseline was
demonstrated (Fig. 5d, e, 6a and b). There was a
statistical significant difference of 1st day uATF3 fol-
lowing AKI onset compared with baseline (p <0.05)
(Fig. 6b). However, uNGAL but not uATF3 showed a
tendency of the higher value at 1 day before AKI
onset (Fig. 6a). To calculate area under receiver op-
erating characteristic (AUROC) curve and sensitivity/
specificity of uNGAL and uATF3 for sepsis-AKI
diagnosis, all time-point data of matched value
between uNGAL and uATF3 from patients with
sepsis-AKI were combined. The gold standard of
sepsis-AKI was Scr ≥0.3 mg/dL from baseline and
the cut-off value of uNGAL and uATF3 was 188 and
12 ng/mL, respectively, from the mean level of
sepsis-non-AKI group. We found that AUROC of
uNGAL and uATF3 were 64% and 84%, respectively
(Fig. 7). It seems that uATF3 showed a comparable
sensitivity but higher specificity for sepsis-AKI diag-
nosis in comparison to uNGAL. Urine NGAL and
uATF3 performance with different cut-off values
were demonstrated (Table 2). At 1 day before AKI,
the sensitivity of uNGAL and uATF3 were compar-
able but uATF3 showed higher specificity.
In a multiple logistic regression model, patients
with uNGAL at 150 ng/mL had a fivefold risk of
AKI (OR, 5.6; 95% CI, 3.1 to 7.4); those patients with
uATF3 at 12 ng/mL showed 8-fold higher risk of de-
veloping AKI (OR, 8.2; 95% CI, 5.6 to 12.8) (Table 3).
Presence of comorbidity was associated with an OR
of 2.8 (95% CI, 1.6 to 3.8), and high APACHE score
were associated with an OR of 4.2 (95% CI, 1.9 to
6.6). Regarding the risk prediction model, a fair
performance was obtained (Hosmer–Lemeshow P
value =0.77), with AUC = 0.79 (95% CI, 0.70 to 0.88).
To determine the addition values of uNGAL and
uATF3 to the clinical model (age, comorbidity and
APACHE II score), the category-free NRI (cfNRI)
was calculated (Table 4). Urine NGAL, uATF3, and
both values in combination enhanced predictive risk
in 67%, 69% and 49%, respectively, in sepsis-AKI pa-
tients, and 35%, 44% and 52%, respectively, in sepsis-
non-AKI patients. In addition, uNGAL, uATF3, and
the combined biomarkers improved overall cfNRI in
75%, 83% and 80%, respectively (Table 4).
Discussion
Urinary exosome is an interesting source of urine bio-
marker and urinary exosomal ATF3 (uATF3) was a can-
didate of early AKI biomarker [20, 21]. ATF3 and NGAL
expressed in kidney histology earlier than Scr of sepsis
mice. Indeed, the analysis of urine patients with sepsis-
AKI demonstrated higher uNGAL and uATF3 in com-
parison with either healthy volunteer or non-sepsis
AKI. Moreover, only uATF3, but not uNGAL, increased
during the early period of sepsis-AKI with the better
area under receiver operating characteristic curve
(AUROC) over uNGAL.
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To see if ATF3 is a good candidate for the early
sepsis-AKI biomarker, we explore in a mouse model
due to the known sepsis onset in the model but not
in patients. Because sNGAL increased as early as 6 h
after cecal ligation and puncture (CLP) with the on-
set of clinical abnormality consistent with previous
publications [10, 27, 31], we determined 6 h after
CLP as the early phase of sepsis-AKI. Interestingly,
both NGAL and ATF3 expressed in renal tubular
cell at brush border and nuclei, respectively,
suggested different functions of these proteins. In-
deed, NGAL produced and excreted out from differ-
ent cells in response to organs injury to controlling
the extracellular iron reactive oxygen species then
re-absorbed and secreted through the proximal and
distal renal tubular cell, respectively [32]. On the
other hand, ATF3 interfered with several intra-nuclei
transcriptional factors to inhibit pro-inflammatory
cytokine translational processes [22]. Moreover, acti-
vated caspase-3 was also detectable from renal tissue
Fig. 5 The longitudinal follow-up for 7 days of patients either sepsis-AKI or sepsis-non-AKI (a-c) with the dose–response relationship between
biomarker concentration and severity of AKI, Scr versus uNGAL (d) and Scr versus uATF3 (e)
Fig. 6 To clearly demonstrated if new biomarkers could be detected at an early stage of sepsis-AKI, values of urinary neutrophil gelatinase associated
lipocalin (uNGAL) (a) and urinary activating transcriptional factor 3 (uATF3) (b) at baseline, 1 day before and at 1st and 2nd day of Scr higher
than baseline for 0.3 mg/dL was showed. *p <0.05 compared with baseline levels
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at 6 h of CLP by Western blot analysis support the
association of apoptosis and ATF3 or NGAL as pre-
viously described [33]. Despite ATF3 is not specific
to kidney as it was also demonstrated in other or-
gans as previously known [34–36], it seems to be ac-
tivated only in condition with organs injury as there
was no ATF3 expression in sham mice. Then ATF3
in urine should be a better representative renal bio-
marker than serum ATF3. NGAL, on the other hand,
is also not specific to kidney and kidney injury [37]
but it could be used as an early-AKI biomarker
[14, 38, 39]. Although, the early expression of NGAL
and ATF3 in kidney of CLP mice suggested the
possibility of early sepsis biomarker, CLP model was
anuria. Then we test uNGAL, a more specific renal
injury than plasma NGAL, and exosomal uATF3 in
urine patient sample.
Indeed, uATF3 and uNGAL were high in patients
with sepsis-AKI in comparison with the healthy vol-
unteers but with the poor correlation between both
parameters. The correlation is better with the higher
Scr. Perhaps, there were different molecular induction
pathways of both molecules in the different sepsis-
AKI severity. Interestingly, uATF3 was negative in all
healthy volunteers implied the high specificity to
sepsis-AKI.
Fig. 7 The area under the receiver operating characteristic (AUROC) curve analysis of sensitivity and specificity of the urinary neutrophil gelatinase
associated lipocalin (uNGAL) (a) and urinary activating transcriptional factor 3 (uATF3) (b) with the alteration of Scr higher than 0.3 mg/dL as a gold
standard of sepsis-AKI diagnosis
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For exploration of early sepsis-AKI biomarkers, we
collected urine samples of patients with sepsis dur-
ing the first week of the admission to identify the
onset of sepsis-AKI. To show the tendency of bio-
markers toward sepsis-AKI, matched data of uNGAL
and uATF3 from all time-point were combined. As
expected, uATF3 and uNGAL in sepsis-AKI were
higher than sepsis-non-AKI group and uATF3 was
rarely increased in sepsis-non-AKI. In contrast, there
was a baseline level and slightly increase of uNGAL
in healthy volunteers and sepsis-non-AKI during the
follow-up. This implied an easier decision for the
cut-off value of uATF3 than uNGAL. For the clinical
application, uNGAL and uATF3 were analyzed in
comparison with the day of increased Scr due to the
difference onset of sepsis-AKI in these patients.
Surprisingly. uNGAL show a tendency to increase at
1 day before increase in Scr, but non-statistically sig-
nificance, perhaps due to the non-specific response
to infection. The loss of the AKI prediction property
of uNGAL in our study might due to the very subtle
increased in Scr or the non-oliguric septic-AKI in
most of the patients. However, our data derived from
the very strict criteria of new onset of sepsis-AKI
developed during the admission. Nevertheless, only
uATF3 increased at the same days of increased Scr.
This demonstrated the benefit of uAFT3 over
uNGAL in predicting AKI. Despite uATF3 did not
increase before Scr, uATF3 but not uNGAL, would
be a good additive biomarker for supporting the on-
set of AKI in sepsis condition with only a subtle in-
crease of Scr. Further studies are needed.
With all matching data of uATF3 and uNGAL with
the mean values of sepsis-non AKI group as the cut-
off, the sensitivity of uATF3 for sepsis-AKI diagnosis
was comparable with uNGAL with the higher
specificity (Table 3). Indeed, our data demonstrated
the comparable AUROC of uNGAL and proposed
uATF3 as another early sepsis-AKI biomarker
(Table 5).
In short, our results were a proof of concept that urinary
exosome was an interesting source of biomarkers and
urinary exosomal ATF3, in particular, was an interesting
sepsis-AKI biomarker. More studies will be needed for the
proper clinical use of uATF3.
There are several limitations to this study. First, the
exosome extraction and analysis method was too
complicated for a routine biomarker. The requirement
of high urine volume, the normalization by urine
creatinine and the Western blot analysis was in-
convenient. Second, there were only 14% patients
with oliguric sepsis-AKI in our data. Therefore, the
levels of uNGAL and uATF3 in oliguric sepsis-AKI
might be different. Third, although it was a prospect-
ive, cohort study; the number of patients was too
small. However, our results could be sufficient to con-
clude that ATF3 in urine exosome was an interesting
sepsis-AKI biomarker that should be supported in the
larger studies. Finally, the observation was only a
cross-sectional and a short term follow-up data so
the association of these biomarkers and clinical
outcomes was not explored.
Table 2 Urine neutrophil gelatinase-associated lipocalin (uNGAL)
and urine exosomal activating transcriptional factor 3 (uATF3)
performances with predetermined cutoff points
Times Sensitivity Specificity LR+ LR- PPV NPV
uNGAL
Cutoff 100 ng/mL
Baseline 57.1 23.2 0.7 1.9 7.6 83.0
Day-1 98.2 36.4 0.7 1.3 12.1 88.0
Day + 1 90.0 28.1 1.3 0.7 13.8 93.1
Day + 2 100.0 35.4 1.6 0.0 14.7 100.0
Cutoff 150 ng/mL
Baseline 52.2 34.4 0.8 1.6 9.2 85.2
Day-1 97.5 44.3 1.8 0.2 16.5 96.7
Day + 1 71.4 36.3 1.9 0.5 16.9 95.1
Day + 2 83.3 50.2 1.7 0.3 16.0 96.5
uATF3
Cutoff 6 ng/mL
Baseline 57.1 73.2 2.1 0.6 19.1 93.9
Day-1 42.9 73.2 1.6 0.8 15.1 92.0
Day + 1 71.4 80.0 2.3 0.4 20.0 95.6
Day + 2 71.4 90.2 7.3 0.3 44.9 96.6
Cutoff 12 ng/mL
Baseline 57.1 80.2 5.8 0.5 39.4 95.0
Day-1 93.3 85.4 5.7 0.2 38.8 97.9
Day + 1 90.9 88.2 5.7 0.5 38.2 98.9
Day + 2 84.6 67.5 4.7 0.5 37.8 95.5
LR, likelihood ratio; PPV, positive predictive value; NPV, negative predictive value
Day-1 = the day before AKI was diagnosed, Day + 1 = the day after AKI was
diagnosed, Day + 2 = the second day after AKI was diagnosed
Table 3 Multiple logistic regression model
Variables OR CI p-value
uNGAL 5.6 3.1 to 7.4 <0.001
uATF3 8.2 5.6 to 12.8 <0.001
Age (yr) 1.2 1.0 to 1.3 0.06
Comorbidity 2.8 1.6 to 3.8 0.004
APACHE II 4.2 1.9 to 6.6 <0.001
uNGAL at day + 1 at 150 ng/mL and uATF3 at day + 1 at 12 ng/mL were analyzed
with age, comorbidity and APACHE scoreu; ATF3, urinary activating transcriptional
factor 3; uNGAL, urinary neutrophil gelatinase-associated lipocalin; OR, odds
ratio;CI, 95% confidence interval
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Table 5 Summary of the studies in urine and plasma biomarkers for sepsis-related acute kidney injury
Authors (year) Biomarkers AUROC 95% CI Timing of measurement Threshold values Sensitivity Specificity
Urine
Martensson et al. (2010) [12] NGALa (ng/mg creatinine) 0.86 0.68-1.0 12 h following septic shock >68 0.71 1.0
Su et al. (2011) [40] sTREM-1a (pg/mL) 0.92 0.85-0.99 48 h before AKI diagnosisc 69.04 0.94 0.76
Aydogdu et al. (2013) [41] Cys-Ca (mg/L) 0.86 - Within 8 days after
admission
0.106 0.85 0.80
NGALa (ng/mL) 0.80 - 29.5 0.88 0.73
Fan et al. (2014) [30] NGALa (ng/mL) 0.86 0.81-0.93 7 days after onset of sepsis 402 0.89 0.74
Matsa et al. (2014) [42] NGALa (ng/mL) 0.78 - 24 h after admission 350 0.75 0.82
Terzi et al. (2014) [43] α1ma (mg/L) 0.74 - 24 h before AKI onset 47.9 0.88 0.62
Dai et al. (2015) [44] Cys-Ca (mg/L) 0.74 0.64-0.84 24 h before AKI onset N/A N/A N/A
NGALa (ng/mL) 0.88 0.79-0.95 N/A N/A N/A
sTREM-1a (pg/mL) 0.78 0.69-0.87 N/A N/A N/A
The present study ATF3b (ng/mL) 0.84 0.77-0.91 24 h before AKI onset 12 0.93 0.85
NGALb (ng/mL) 0.64 0.54-0.74 150 0.98 0.44
Plasma
Martensson et al. (2010) [12] NGAL (ng/mL) 0.67 0.39-0.94 12 h following septic shock >120 0.83 0.50
Aydogdu et al. (2013) [41] Cys-C (mg/L) 0.82 - Within 8 days of admission 1.5 0.73 0.68
NGAL (ng/mL) 0.44 - N/A N/A N/A
Matsa et al. (2014) [42] NGAL (ng/mL) 0.88 - 24 h after admission 400 0.79 0.75
Nakamura et al. (2014) [45] Presepsin (pg/mL) 0.70 - Within 24 h of admission 670 0.70 0.81
Nakamura et al. (2015) [46] Procalcitonin (ng/mL) 0.88 - Within 24 h of admission 0.42 0.95 0.65
Dai et al. (2015) [44] Cys-C (mg/L) 0.74 0.63-0.84 24 h before AKI onset N/A N/A N/A
NGAL (ng/mL) 0.83 0.74-0.92 N/A N/A N/A
sTREM-1 (pg/mL) 0.75 0.65-0.85 N/A N/A N/A
α1m, alpha-1-microglobulin; AKI, acute kidney injury; ATF3, activating transcriptional factor 3; AUROC, area under the receiver operating characteristic curve; Cys-C,
cystatin-C; N/A, data not available; NGAL, neutrophil gelatinase-associated lipocalin; sTREM-1, soluble triggering receptor expressed on myeloid cells-1
adetection from urinary soluble fraction part
bdetection from urinary exosomal part
cno data were available 24 h before AKI onset
Table 4 Net classification for model improvement with urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine exosomal
activating transcriptional factor 3 (uATF3)
Sepsis-AKI + uNGAL + uATF3 + uNGAL + uATF3
Goodness-of-fit reference 0.69 0.83 0.88
Goodness-of-fit reference + biomarker (s) 0.75 0.86 0.84
AUROC of reference 0.61 (0.55 – 0.63) 0.74 (0.71-0.78) 0.84 (0.80 – 0.88)
AUROC of reference + biomarker (s) 0.64 (0.54-0.74) 0.84 (0.77-0.91) 0.85 (0.81 – 0.90)
P-value (AUC difference) =0.03 <0.0001 =0.11
cfNRI [events; % (CI)] 47.1 (33.9 – 69.8) 69.3 (66.4 – 82.8) 49.2 (25.5 – 56.8)
cfNRI [non-event; % (CI)] 34.8 (25.4 – 52.3) 44.4 (30.8 – 51.0) 51.8 (43.4 – 58.9)
cfNRI [% (CI)] 74.9 (63.7 – 88.9) 82.5 (74.8 – 90.1) 79.7 (70.8 – 88.8)
The reference is the multiple regression model with age, comorbidity and APACHE II score with uNGAL and uATF3. The calibration of the model was performed
by using Hosmer–Lemeshow goodness-of-fit test. AUROC, area under the receiver operating characteristic curve; cfNRI, category-free net reclassification improvement;
CI, 95% confidence interval; uATF3, urinary activating transcriptional factor 3; uNGAL, urinary neutrophil gelatinase-associated lipocalin
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Conclusion
This study identifies ATF3, a transcriptional factor; in
urine exosome was an interesting sepsis-AKI biomarker.
Since uATF3 could not be detected in most of the
patients with sepsis-non-AKI, the qualitative test of
uATF3 might be adequate for detecting sepsis-AKI. In
contrast, with the baseline of uNGAL, the debates on
the cut-off values of uNGAL for sepsis-AKI are still on-
going. Our results were also a proof of concept that urine
exosomes were an interesting source of urine biomarkers.
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